ABUS vs COP
Arbutus Biopharma Corp (ABUS) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the ABUS and COP stock pages for the full models.
Not investment advice.